Friday, May 7, 2021
8:30 - 9:45  
(9:45 - 10:00)

Introduction to the Programme

Harley Eisman, MD, Co-Founder, Hereditary Breast and Ovarian Cancer Foundation, Montréal, QC, Canada

William Foulkes, MBBS, PhD, Director, Program in Cancer Genetics, McGill University, Montréal, QC, Canada

Insight from large datasets of women with breast cancer
10:00 - 11:45

CHAIR: Stephen Chanock¸ MD, National Cancer Institute, Rockville, MD, USA

10:00 - 10:20

Population-based studies of breast cancer risk in association with established and candidate breast cancer susceptibility genes

Fergus Couch, PhD, Mayo Clinic, Rochester, MN, USA

10:20 - 10:40

Generation and analysis of genomic data at population level: the UK experience

Clare Turnbull, MD, PhD, MFPH, Institute of Cancer Research, London, UK

10:40 - 10:50

Proffered paper 1 (S9-PP1)
Breast Cancer Risk Genes: Association Analysis of Rare Coding Variants in 34 Genes in 60,466 Cases and 53,461 Controls from the BRIDGES Project

Douglas Easton, PhD, University of Cambridge, Cambridge, UK

10:50 - 11:00

Proffered paper 2 (S9-PP2)
Are Germline Heterozygous Variants in NTHL1 Associated with Breast Cancer Predisposition? An International Multi-center Study of 46,000 Subjects

Ian Campbell, PhD, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia

11:00 - 11:10

Proffered paper 3 (S9-PP3)
A Moderately Rare Unstable FANCI c.1813C>T; p.L605F Is Associated with Familial Ovarian Cancer

Caitlin Fierheller, BSc, PhD Candidate, McGill University, Montréal, QC, Canada

11:10 - 11:20

Proffered paper 4 (S9-PP4)
The Contribution of Germline Pathogenic Variants Beyond BRCA1/2/PALB2 to Contralateral Breast Cancer in Women With a Younger Onset First Breast Cancer – a WECARE Study

Marc Tischkowitz, MD, PhD, University of Cambridge, Cambridge, UK

11:20 - 11:45

Question and discussion period (all speakers)

11:45 - 13:00  
Special Interest Groups (SIGs)
13:00 - 14:00

Moderated one-hour interactive discussions with the aim of fostering bilateral knowledge transfer. Choice of the following 2 SIGs.

SIG 5:

Hereditary prostate, pancreas and male breast cancer: Research updates and surveillance recommendations

In this session, the three presenters will discuss the latest research on prevention, early diagnosis and treatment of three cancers that are associated with germline mutations in HRD genes. Attendees will be encouraged to send in questions relating to these topics in advance for discussion at the SIG.

  • Elena Castro, MD, PhD, CNIO-IBIMA Genitourinary Cancer Research Unit, Institute of Biomedical Research in Malaga (IBIMA), Málaga, Spain

  • George Zogopoulos, MD, PhD, McGill University Health Centre, Montréal, QC, Canada

  • Justin Lorentz, CGC, Sunnybrook Odette Cancer Centre, Toronto, ON, Canada

SIG 6:

Ovarian cancer – a multi-faceted view

Ovarian cancer is one of the most preventable cancers. In this unique session, five leading experts will discuss the epidemiology of, and inherited contribution to, ovarian cancer, the role of risk assessment in management, the molecular genetics and pathology of the main subtypes of ovarian cancer, and where new treatments are taking the field.

  • Paul Pharoah, BM, BCh, PhD, University of Cambridge, Cambridge, UK (session lead)

  • Antonis Antoniou PhD, University of Cambridge, Cambridge, UK

  • Blaise Clarke, MD, University Health Network, Toronto, ON, Canada

  • Ursula Matulonis, MD, Dana-Farber Cancer Institute, Boston, MA, USA

  • Britta Weigelt, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, USA

The Marla Miller Memorial Lecture
14:30 - 15:45

Introductory Remarks

William Foulkes, MBBS, PhD, Director, Program in Cancer Genetics, McGill University, Montréal, QC, Canada

The Icelandic approach to population-based testing for high risk alleles for breast and ovarian cancer

Kári Stefánsson, MD, PhD, deCODE Genetics, Reykjavík, Iceland

Presentation by the Miller Family

Closing Remarks

Harley Eisman, MD, Co-Founder, Hereditary Breast and Ovarian Cancer Foundation, Montréal, QC, Canada

Marla Miller-Gross
Marla Miller-Gross passed away less than two years after being diagnosed with "routine" breast cancer, months shy of her fortieth birthday. Marla's courage in opting for genetic testing has touched lives far far beyond those that she befriended while living.

Out of Marla's tragedy, HBOC was born and the drive to improve the outcome of women and families with hereditary breast and ovarian cancer.